- Our Doctors
- Dr Marcus Dreosti
Dr Marcus Dreosti
BSc, Hons LLB, MBBS (Hons) FRANZCR, GenesisCare Australia Chief Medical Officer, Radiation Oncologist
My aim is to offer the highest quality of evidence-based individualised care possible to every patient, supporting them on their cancer journey
Languages spoken
English
Overview
Centres
Clinical interests
Clinical interests include breast, prostate, gastrointestinal & gynaecological.
Dr Marcus Dreosti is a Senior Radiation Oncologist at GenesisCare South Australia and the Chief Medical Officer of GenesisCare Australia.
Dr Dreosti graduated with Honours degrees in both Law and Medicine from Adelaide and Flinders Universities respectively. He undertook specialist training in Radiation Oncology at St Vincent’s Hospital, Sydney and the Royal Adelaide Hospital.
He completed Clinical Fellowships in Singapore and Darwin before returning to Sydney to assume the role of Staff Specialist at Liverpool and Macarthur Cancer Centres – a sub-specialised tertiary cancer department. During this time, he focused on the treatment of breast cancer and, further was part of the team who introduced a stereotactic radiotherapy program to the centres for specific tumour types. In addition, he acted as a conjoint lecturer at the University of Western Sydney (UWS) Medical School, where he taught oncology and clinical skills to medical students.
Dr Dreosti then moved home to Adelaide where he is now a Senior Radiation Oncologist at GenesisCare, Medical Director in South Australia and is the Chief Medical Officer of GenesisCare Australia.
His clinical interests include breast, prostate, gastrointestinal, and gynaecological cancers.
Dr Dreosti is an Examiner for the Royal Australian and New Zealand College of Radiologists (RANZCR) Registrars undertaking their final specialist examinations and is an Executive Director of the Australian Society of Breast Disease. He is also a regular presenter at medical conferences.
Research interests
Dr Dreosti is engaged in external clinical trials across different tumour types. Significant internal focus on collection of standardised data to facilitate audit and peer review to drive treatment quality.
Professional memberships
- RANZCR
- ESTRO
- ASTRO
- ANZHNS
- ASBD
Publications
- Moderate hypofractionation for prostate cancer: A user’s guide
- Adoption of hypofractionated radiation therapy for early breast cancer in private practice: the GenesisCare experience 2014–2016
- A Comparison study of treatment techniques for the reduction of submandibular gland dose: A retrospective study
- An Australian and New Zealand Practice Survey on Breast Radiotherapy
- Radiotherapy for Parotid Ig-G4 related disease
Disclaimer:
This website is provided for information purposes only. Nothing on this website is intended to be used as medical advice, or to diagnose, treat, cure or prevent any disease. It should not be used as a substitute for your own health professional's advice. Any medical procedure or treatment carries risks. Before proceeding with treatment, you should discuss the risks and benefits of the treatment with an appropriately qualified health practitioner. Individual treatment outcomes and experiences will vary.